Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.

ABSTRACT:

Study objective

To develop and validate a predictive model for glucose change and risk for new-onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).

Design

Randomized multicenter clinical trial.

Patients

A total of 735 white or African-American men and women with uncomplicated hypertension.

Measurements and main results

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 a

SUBMITTER: Moore MJ 

PROVIDER: S-EPMC4227953 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature